Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Intangibles (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Intangibles for 2 consecutive years, with $18.0 million as the latest value for Q4 2025.

  • Quarterly Intangibles rose 15.29% to $18.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.0 million through Dec 2025, up 15.29% year-over-year, with the annual reading at $18.0 million for FY2025, 15.29% up from the prior year.
  • Intangibles for Q4 2025 was $18.0 million at Day One Biopharmaceuticals, down from $18.8 million in the prior quarter.
  • The five-year high for Intangibles was $20.4 million in Q1 2025, with the low at $15.6 million in Q4 2024.